key: cord-0709128-dkhy3qq8 authors: Dick, Aharon; Rosenbloom, Joshua I; Karavani, Gilad; Gutman-Ido, Einat; Lessans, Naama; Chill, Henry H title: Safety of 3rd SARS-CoV-2 vaccine (booster dose) during pregnancy date: 2022-04-07 journal: Am J Obstet Gynecol MFM DOI: 10.1016/j.ajogmf.2022.100637 sha: 30b296b02cf572a2da95a48da8f2ac71a0dfe86d doc_id: 709128 cord_uid: dkhy3qq8 Background COVID-19 during pregnancy is associated with adverse outcomes for mother and fetus. SARS-CoV-2 vaccination has significantly reduced the risk of symptomatic disease. Several studies have reported the safety of SARS-CoV-2 vaccination during pregnancy, with no adverse effect on obstetric outcomes. However, obstetric outcomes following a booster dose of the SARS CoV-2 vaccination during pregnancy have yet been published. Objective To examine the association between booster dose of the SARS CoV-2 vaccination during pregnancy and obstetric outcomes. Methods A retrospective cohort study of women who delivered between July and October 2021 at a large tertiary medical center. We compared women who received the booster vaccine during pregnancy to women who were not vaccinated and to those who had only received two vaccines. Primary outcomes were the incidence of preterm labor and of small for gestational age. Secondary outcomes were other maternal and neonatal complications. A secondary analysis investigating the association between the timing from vaccination to delivery and outcomes was also performed. Multivariable logistic regression models were used to adjust for potential confounders. Results There were 6507 women who met the inclusion criteria: 294 women received three vaccines, 2,845 women received only two vaccines and 3,368 were unvaccinated. Patients receiving three vaccines were older and more likely to smoke compared to unvaccinated patients. No differences were noted between triple-vaccinated, twice-vaccinated and unvaccinated groups with regards to preterm birth and small for gestational age. Regarding secondary outcomes, women in the triple vaccine group had higher rates of PPH (9.5 vs 3.21%, P<0.001), gestational diabetes (12.2 vs. 8.3 %, p=0.02), and were less likely to have hypertensive disorders of pregnancy (0% vs 1.4%, p=0.041) compared to the unvaccinated group. Compared to twice-vaccinated patients, patients with three vaccines were more likely to experience PPH (9.5 vs. 3.5%, p<0.001), and were less likely to have a low umbilical artery pH (0.7 vs 6.1%, p<0.001). In the sensitivity analysis comparing patients delivered within 2 weeks of the third vaccination (n=53) to those delivered at least 6 weeks after vaccination (n=96), there were no differences in the rates of SGA, preterm birth, PPH, or cesarean delivery. Conclusion The booster dose of the SARS-CoV-2 vaccine during pregnancy was not associated with adverse obstetric outcomes compared to unvaccinated or twice-vaccinated women. However, higher rates of PPH were observed. Further studies on a larger scale are needed to confirm these findings. With over than 5 million casualties worldwide, Coronavirus disease 2019 (COVID-19) has been a major source of concern to the international medical community.(1) Evidence suggests that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected pregnant women are at higher risk of hospitalization and complications, including admission to Intensive Care Unit (ICU) and invasive mechanical ventilation (IMV) compared to the general population. (2) Moreover, several studies have reported the COVID-19 infection during pregnancy is associated with adverse maternal and neonatal outcomes including preterm birth and small for gestational age birthweight (3) (4) . SARS-CoV-2 vaccination was introduced in late 2020, significantly reducing morbidity and mortality in the general population (5) . Although, the original clinical trials of the pharmaceutical companies did not include pregnant women, several retrospective studies have reported the safety of SARS-CoV-2 vaccination during pregnancy, showing comparable pregnancy outcomes to the unvaccinated population (6) (7) . The first prospective trial to include this high risk population began early 2021 (Pfizer BioNTech, ClinicalTrials.gov identifier: NCT04754594) with primary results due August 2022 (8). The booster dose (third vaccination) was introduced in Israel at the end of July 2021 due to the surge in cases involving the Delta variant and the increase in general infection rates (9) . Individuals were advised to receive the booster dose if five months or more had passed since the second vaccine. A large trial including pregnant women found that the boosted population were at a lower risk to develop severe COVID-19-related outcomes. (10) To the best of our knowledge, maternal and neonatal outcomes following a booster dose of the SARS CoV-2 vaccination during pregnancy have not yet been published. Therefore, we conducted a retrospective cohort study to examine the association between receipt of the third vaccine and adverse obstetric outcomes. This is a retrospective cohort study conducted at a large tertiary university affiliated hospital. The study group included women with a singleton pregnancy who received the booster vaccine during pregnancy and who delivered in the period July-October 2021. The control group included women with a singleton pregnancy who were not vaccinated. As a secondary analysis, we also compared women receiving the booster in pregnancy to those who had only received two vaccines. Exclusion criteria included multiple pregnancy, COVID-19 infection during or before pregnancy, or unknown timing of vaccination. During the study period the vaccines used in Israel were either the Pfizer BioNTech (BNT162b2) or Moderna vaccine. Clinical and obstetric data were collected, including maternal age, body mass index (BMI), obstetric history and smoking. The co-primary outcomes were preterm birth, defined as birth before 37 weeks gestation, and small for gestational age, defined as birthweight below the tenth percentile for gestational age and sex using local birthweight standards (11) . Secondary outcomes included gestational diabetes, mode of delivery, hypertensive disorders of pregnancy, post-partum hemorrhage, intrauterine fetal demise, 5-minute Apgar score, and umbilical arterial pH and base excess. Gestational age was assigned based on first trimester ultrasound. Gestational diabetes was diagnosed using the two-step test as with the Carpenter-Coustan criteria used for the 100g glucose tolerance test (12) . Hypertensive disorders of pregnancy were also defined using the criteria of the American College of Obstetricians and Gynecologists. Postpartum hemorrhage was defined as estimated blood loss greater than 500mL for a vaginal delivery or 1,000 mL in a cesarean delivery. Descriptive statistics including medians and interquartile ranges are presented for the obstetric and clinical covariates. Comparisons were made between patients receiving the third vaccine with unvaccinated patients and separately with patients vaccinated twice. Variables were checked for normality using the Kolmogorov-Smirnov test. Continuous variables were compared using either the ttest or the Mann-Whitney U test as appropriate. Categorical variables were compared using chi-square or Fisher exact test. To assess the potential association between the booster vaccine and the outcomes, multivariable logistic regression was performed. Potential confounders including maternal age, BMI, nulliparity, and smoking were added to the model. Additionally, we performed a sensitivity analysis to address the timing between vaccination and delivery. We compared outcomes of patients delivered within 2 weeks of the third vaccine to those delivered more than 6 weeks after receipt of the third vaccine. Analysis was performed in Stata 14 (StataCorp, College Station, TX). The study was approved by the local Institutional Review Board (HMO-21-0342). There were 294 women in the study group. These were compared to a control group of 3,368 unvaccinated women and 2,845 women who had received only two vaccines. The median gestational age at third vaccine was 34.9 weeks (range 23-40, IQR 32.5, 37.0). The median time from receipt of the third vaccine to delivery was 4.5 weeks (IQR 2.7, 6.9 weeks). Patients receiving three vaccines were older and more likely to smoke compared to unvaccinated patients (Table 1) . Patients who had received three vaccines were slightly older than patients who had received only two vaccines, but otherwise did not significantly differ ( Table 2) . Obstetric outcomes for triply-vaccinated compared to unvaccinated patients are shown in Table 1 . No differences were noted between triple-vaccinated and unvaccinated groups with regards to preterm birth and small for gestational age. Regarding secondary outcomes, women in the triple vaccine group had higher rates of PPH (9.5 vs 3.21%, P<0.001), gestational diabetes (12. (Table 3) . Compared to doubly-vaccinated patients, patients with three vaccines were more likely to experience PPH (9.5 vs. 3.5%, p<0.001), and were less likely to a low umbilical artery pH (0.7 vs 6.1%, p<0.001) ( Table 2 ). There was no association between triple-vaccination and either of the co-primary outcomes. In multivariable logistic regression (Table 4) , these two secondary outcomes remained significant: low umbilical artery pH (aOR 0.11 ( 95%CI 0.027, 0.45); PPH (aOR 3.34 (95% CI 2.07, 5.39)). However, umbilical artery gas information was only available for 94 (32%) of the triply-vaccinated patients and 1,616 (57%) of the doubly-vaccinated patients. In the sensitivity analysis comparing patients delivered within 2 weeks of the third vaccine receipt (n=53) to those delivered at least 6 weeks after receipt (n=96), there were no differences in the rates of SGA, preterm birth, PPH, or cesarean delivery. In this study we report on obstetric outcomes following the booster dose of SARS-CoV-2 vaccine during pregnancy. No increase in preterm birth or small for gestational age was demonstrated compared to women who were not vaccinated or to those vaccinated twice. There was, however, a higher rate of postpartum hemorrhage in the triple vaccinated group, although the potential mechanism that may underlie this association is unclear. Additionally, we found that the incidence of low (<7.1) umbilical artery pH was lower in the triple vaccine group compared to the double vaccine group, yet data regarding this variable were available for few patients. To date the question of safety of the booster dose of SARS-CoV-2 vaccine during pregnancy has yet to be addressed. Recent studies found that early vaccination during pregnancy was associated with an antibody waning throughout pregnancy. (15) . Those receiving a third booster dose were found to have significantly higher maternal and neonatal antibody levels. (15, 16) . These studies support the value of our objective. We found that women receiving the booster dose vaccine during pregnancy did not suffer from adverse maternal or neonatal outcomes. With the continuing COVID-19 pandemic on the one hand, and waning of the immunity effect of the SARS-CoV-2 vaccine on the other, there is a need to evaluate the maternal and neonatal outcomes of additional vaccine doses during pregnancy. Our study provides a first glimpse to this topic, although larger scale studies need to be done to reinforce our findings. The main strength of our study is its originality: To the best of our knowledge, we are the first to report neonatal outcomes of women receiving the booster dose of SARS-CoV-2 vaccine during pregnancy. Furthermore, we were able to compare the study group to both vaccinated and unvaccinated women, allowing for a better understanding of the specific effects of the booster dose. Besides its retrospective design, this study has several limitations. The women in our study group were older and had higher rates of smokers compared to the un-vaccinated group-perhaps confounding our results. Second, we did not have the information regarding the immediate adverse reactions following vaccination. Finally, we were missing data on potential confounders including a history of preterm birth. The booster dose of the SARS-CoV-2 vaccine during pregnancy was not associated with adverse obstetric outcomes compared to unvaccinated or double-vaccinated women. However, higher rates of PPH were observed. Further studies on a larger scale are needed to confirm this finding. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and metaanalysis Maternal COVID-19, vaccination safety in pregnancy, and evidence of protective immunity Maternal and Neonatal Morbidity and Mortality among Pregnant Women with and without COVID-19 Infection: The INTERCOVID Multinational Cohort Study BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study Changes in infectivity, severity and vaccine effectiveness against delta COVID-19 variant ten months into the vaccination program: The Israeli case Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study Birthweight standards in the live-born population in Israel Gestational Diabetes Mellitus Safety of SARS-CoV-2 vaccination during pregnancy-obstetric outcomes from a large cohort study COVID-19 vaccination during pregnancy: coverage and safety The effect of gestational age at BNT162b2 mRNA vaccination on maternal and neonatal SARS-CoV-2 antibody levels Association of Gestational Age at Coronavirus Disease 2019 (COVID-19) Vaccination, History of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, and a Vaccine Booster Dose With Maternal and Umbilical Cord Antibody Levels at Delivery